RHOFADE (nda208552)- (1%)

Generic Name	OXYMETAZOLINE HYDROCHLORIDE	Innovator	MAYNE PHARMA
Dosage	1%
ParaIV Filing	Yes	505(b)2 Filing	No
Last Patent Expiry	2035-Jun-11	NCE Excl Expiry	Expired
ODE Expiry	None	NP Expiry	2020-Jan-18
GAIN Expiry	None	Drug Complexity	No
Indication	RHOFADE™ is an alpha1A adrenoceptor agonist indicated for the topical treatment of persistent facial erythema associated with rosacea in adults.

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
1	1	1

Other Developers

Total Other Developers	1

Drugs with Suitability

Drugs with Suitability	No

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
1%	**	**	Down	-	-

Drug Sales

NDA Sales Available	Total Generic Sales Available
Yes	0

Manufacturing Details of RHOFADE